Biodexa Pharmaceuticals PLC, a public limited liability company incorporated in England and Wales, referred to as Midatech, is a specialty pharmaceutical company focused on the development and commercialization of a variety of therapeutic products, leveraging its nanotechnology and sustained-release technologies to enhance the delivery of medicines in critical diseases and meet medical needs. These diseases include diabetes, certain cancers such as liver, pancreas, ovarian cancer and brain (glioblastoma), and neurological/ophthalmic conditions. Midatech's strategy is to develop partners in rare cancers and other indications, keep its products in-house, and accelerate its business growth through strategic acquisitions of complementary products and technologies.
